Clinical Trials Logo

NSCLC, Squamous or Non-Squamous clinical trials

View clinical trials related to NSCLC, Squamous or Non-Squamous.

Filter by:
  • None
  • Page 1

NCT ID: NCT04432857 Active, not recruiting - Cervical Cancer Clinical Trials

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Start date: August 20, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase Ib study to evaluate the safety and preliminary efficacy of AN0025 in combination with pembrolizumab in patients with locally advanced/metastatic tumors. It will include a dose-limiting toxicity observation phase followed by an expansion phase. All enrolled patients will be treated with AN0025 and Pembrolizumab until the patient experiences disease progression, unacceptable toxicity or withdraws consent, or for a maximum of 35 cycles (approximately 2 years). The dose of pembrolizumab will remain constant at 200 mg every 3 weeks (Q3W) for each dose level of AN0025 and in each cohort.